BBO-10203 inhibits RAS-driven PI3Kα activity in tumor cells without changes in glucose metabolism
Dec. 27, 2023
Researchers from Bridgebio Pharma Inc. recently presented BBO-10203, a first-in-class, orally bioavailable, covalent small-molecule candidate designed to inhibit RAS-driven PI3Kα activity without affecting glucose metabolism.